Cen FRS, Hernández GK, Mena SS, Zamora CD, Zeledón LJ, Herrera MÁ

Language: Spanish
References: 17
Page: 58-66
PDF size: 199.41 Kb.

ABSTRACT

The Chronic Kidney Disease is a group of heterogeneous disorders that affect the structure and function of the kidney, which manifest themselves in different ways depending on the underlying cause and the stage of the disease. The complications are multisystemic and can compromise the life of the patient. The hyperphosphatemia in advanced CKD has been related to a high morbidity and mortality. The treatment aim is treating the underlying causes, mainly Diabetes Mellitus and Arterial Hypertension. In addition, the pharmacological and non-pharmacological objective is to reduce blood pressure in the kidneys and albuminuria. This is more important in a country like Costa Rica, where a chronic kidney disease has been described that is not related to the traditional risk factors, known as Mesoamerican Renal Disease.

REFERENCES

1. Levey AS Coresh J. Chronic kidney disease. The Lancet.2012;379: 165-176.

2. KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013; 3:1-14

3. Levey A, Cattran D, Friedman A, Miller W, Sedor J, Tuttle K et al. Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009;54(2):205-226.

4. Fox C Neuhaus K Vassalotti J. Importance urine albumin-creatinine ratio in the diagnosis andprognosis of chronic kidney disease. OA Nephrology. 2013; 1(3):21

5. Romagnani P Remuzzi G Glassock R et al. Chronic kidney disease. Nat. Rev. Dis. Primers. 2017; 3:1-24.

6. Longo DL Fauci AS Kasper DL Hauser SL Jameson JL Loscalzo J. Harrison principios de medicina interna. McGraw‐Hill.2012; 18(2): 2308-2321Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kideny Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2017; 7(1).

7. Joret M et al. Papel del fósforo en la enfermedad renal crónica. Nefrología (Madr.) 2013; 4(2): 02-10.

8. Bernuy J Gonzales G. Metabolismo mineral óseo en pacientes con enfermedad renal crónica: revisión sobre su fisiopatología y morbimortalidad. Rev Peru Med Exp Salud Publica 2015;32(2): 326.

9. Skorecki K Chertow G Marsden P Taal M Yu A. Brenner & Rector’s the kidney. 2016; 10:1774-1776.10.

10. Ruospo M Palmer SC Natale et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database of Systematic Reviews. 2018; Issue 8.

11. Jameson J De Groot L. Endocrinology: Adult and Pediatric. 2016;7ed:1215-1224.

12. Gilligan S Raphael K. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes. Advances in Chronic Kidney Disease. 2017;24(5):315-318.

13. Stevens PE et al. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11):825-830.

14. Fishbane S Chittineni H Packman M Dutka P Ali N Durie N. Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial. Am J Kidney Dis. 2009;54(4):647-652.

15. Organización Panamericana de la Salud. La Enfermedad Renal Crónica en Comunidades Agrícolas de Centroamerica: Documento Conceptual. Washington. 2013; 1:01-05.

16. R Herrera C Orantes M Almague et al. Características clínicas de la enfermedad renal crónica de causas no tradicionales en las comunidades agrícolas salvadoreñas. MEDICC. 2014;16(2):42-46.

17. A Rivera E Méndez. Mortalidad y egresos hospitalarios por enfermedad renal crónica compatibles con enfermedad crónica de causas no tradicionales, Costa Rica. Acta méd costarric. 2016;58(1):06.